A Phase II Trial Of Ofatumumab In Older (greater than or equal to 70 Years) Patients With Previously Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas.

Trial Profile

A Phase II Trial Of Ofatumumab In Older (greater than or equal to 70 Years) Patients With Previously Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications B cell lymphoma; Follicular lymphoma
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Actual initiation date changed from Jan 2011 to jun 2011 as reported by ClinicalTrials.gov.
    • 23 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top